Stereotaxis and Abbott Combine Technologies in First Integrated Procedures to Treat Arrhythmia Patients
18 Julho 2023 - 10:18AM
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical
robotics for minimally invasive endovascular intervention, today
announced the first patients have been successfully treated
utilizing Abbott’s EnSite™ X EP System with Stereotaxis’ Robotic
Magnetic Navigation System.
The combination of Abbott’s leading cardiac
mapping system with Stereotaxis’ advanced robotic technology brings
together highly detailed real-time diagnostic information with the
unprecedented precision and stability of robotics during therapy
delivery. The integration of these technologies was announced at
Heart Rhythm 2023. The first integrated procedures were
successfully conducted by Dr. Sing-Chien Yap and Dr. Tamas
Szili-Torok at Erasmus Medical Center in Rotterdam, The
Netherlands, and by Dr. Burkhard Hügl at Marienhaus St. Elisabeth
Hospital in Neuwied, Germany.
“The integration of advanced mapping with the
precision and safety of robotics helps provide the best therapy for
patients and an enhanced workflow for physicians,” said Dr.
Sing-Chien Yap. “These pioneering integrated robotic EnSite X
procedures went very well, with successful treatment of patients
with atrial and ventricular arrhythmias in a safe and efficient
fashion.”
“We have long championed the benefits of open
interoperability in electrophysiology as a way to pair the most
suitable technologies for each patient,” added Dr. Tamas
Szili-Torok. “Full integrated use of EnSite X with Stereotaxis
robotic technology worked smoothly and we are delighted to
contribute to this progress.”
“The community of physicians who are pioneering
robotics in electrophysiology have long championed increased
integrations,” said Dr. Burkhard Hügl. “The integration of both
systems enables me to address the most complex arrhythmia patients.
I am very pleased with this technological advance and the growing
recognition that robotics plays an important role for the
electrophysiology field.”
About StereotaxisStereotaxis
(NYSE: STXS) is a pioneer and global leader in innovative surgical
robotics for minimally invasive endovascular intervention. Its
mission is the discovery, development and delivery of robotic
systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
expand access to minimally invasive therapy, and enhance the
productivity, connectivity, and intelligence in the operating room.
Stereotaxis technology has been used to treat over 100,000 patients
across the United States, Europe, Asia, and elsewhere. For more
information, please visit www.stereotaxis.com.
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially. Factors that would cause or contribute to such
differences include, but are not limited to, the Company's ability
to manage expenses at sustainable levels, acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its technology, competitive factors, changes resulting
from healthcare policy, dependence upon third-party vendors, timing
of regulatory approvals, the impact of pandemics or other
disasters, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments because some of these purchase orders and other
commitments are subject to contingencies that are outside of the
Company's control and may be revised, modified, delayed, or
canceled.
Stereotaxis Contacts:David L.
FischelChairman and Chief Executive Officer
Kimberly PeeryChief Financial Officer
314-678-6100Investors@Stereotaxis.com
Stereotaxis (AMEX:STXS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Stereotaxis (AMEX:STXS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024